Geron Corp - GERN STOCK NEWS

Geron Corporation (NASDAQ: GERN) will release its Q2 2022 financial results on August 11, 2022, after the market closes. The details will be available on the company’s website. A conference call to discuss these results and upcoming milestones is scheduled for 4:30 p.m. ET on the same day. The call will be accessible via a live webcast on their site, with an archive available for 30 days. Geron is focused on developing its telomerase inhibitor, imetelstat, for hematologic malignancies and is conducting two Phase 3 trials.

Geron Corporation (Nasdaq: GERN), a biopharmaceutical firm focused on hematologic malignancies, announced that CEO John A. Scarlett will participate in a fireside chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 10, 2022, at 12:35 p.m. ET. The event will be webcasted through the Investor Relations section on Geron's website and will be available for replay for 30 days post-event. Geron is currently advancing two Phase 3 trials: IMerge for lower risk myelodysplastic syndromes and IMpactMF for refractory myelofibrosis.

Geron Corporation (Nasdaq: GERN) has granted non-statutory stock options for 405,800 shares to new employees as part of their employment inducements. These options, issued on July 20, 2022, have an exercise price of $1.94 per share, matching the stock's closing price on the grant date. They feature a 10-year term and vesting over four years. Geron is focused on developing imetelstat, a telomerase inhibitor, for hematologic malignancies, with two ongoing Phase 3 clinical trials: IMerge and IMpactMF.

Geron Corporation announces an expansion of its loan facility with Hercules Capital and Silicon Valley Bank, increasing access from $75 million to $125 million. This amendment allows for an additional $50 million in potential non-dilutive capital in 2023, crucial for the company as it anticipates top-line results from the Phase 3 IMerge trial in January 2023. Funding aims to support operations and potential commercialization of imetelstat until mid-2024.

Geron Corporation (Nasdaq: GERN) has granted a non-statutory stock option to purchase 70,000 shares of common stock to a new employee as an induction measure. This option was granted on June 15, 2022, with an exercise price of $1.30 per share, equal to the stock's closing price on that date. The option vests over four years, starting with 12.5% after six months, subject to continued employment. Geron, focused on developing a telomerase inhibitor for hematologic malignancies, is conducting two Phase 3 trials: IMerge and IMpactMF.

Geron Corporation (NASDAQ: GERN) has appointed Faye Feller, M.D., as Executive Vice President and Chief Medical Officer effective July 9, 2022. She succeeds Dr. Aleksandra Rizo, who will move to a consulting role after leading imetelstat's development. Dr. Feller has significant experience with imetelstat, having been involved in its development at Geron and previously at Janssen. The company anticipates top-line results from the IMerge Phase 3 trial in early January 2023, which could lead to a New Drug Application submission for imetelstat in lower risk myelodysplastic syndromes.

Geron Corporation (Nasdaq: GERN) has granted non-statutory stock options for an aggregate of 327,400 shares to new hires, effective May 18, 2022. The options have an exercise price of $1.30 per share and a 10-year term, vesting over four years. This grant aligns with Nasdaq Listing Rule 5635(c)(4). Geron is engaged in developing imetelstat, a first-in-class telomerase inhibitor, currently in two Phase 3 trials: IMerge and IMpactMF, targeting hematologic malignancies.

Geron Corporation (NASDAQ: GERN), a biopharmaceutical company focused on hematologic malignancies, announced that CEO John A. Scarlett will present at the H.C. Wainwright Global Investment Conference. The on-demand presentation starts on May 24, 2022, at 7 a.m. ET. A webcast will be accessible in the Investor Relations section of Geron's website, with an archive available for 30 days after the event. Geron is advancing its lead candidate, imetelstat, through two Phase 3 trials: IMerge for lower risk myelodysplastic syndromes and IMpactMF for refractory myelofibrosis.

Geron Corporation (Nasdaq: GERN) reported its Q1 2022 financial results, highlighting a net loss of $30.1 million, unchanged EPS at $0.09, and revenues of $123,000. The company has $178 million in cash and marketable securities and completed a public offering in April, raising approximately $70 million. The company anticipates sufficient resources to support operations through the end of 2023. Key milestones include the upcoming Phase 3 IMerge trial results and the initiation of the IMproveMF study, aiming to enhance treatment options for hematologic malignancies.